Prulifloxacin: Clinical studies of a broad-spectrum quinolone agent

Future Microbiology

Volumn 4, Issue 1, 2009, Pages 13-24

  Giannarini, Gianluca ^a   Tascini, Carlo ^b   Selli, Cesare ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Chronic bronchitis; Clinical trials; Fluoroquinolones; Gastroenteritis; Multiple drug resistance; Prostatitis; Prulifloxacin; Pseudomonas aeruginosa; Ulifloxacin; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; ANTIBIOTIC AGENT; CIMETIDINE; CIPROFLOXACIN; FENBUFEN; GREPAFLOXACIN; IRON; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PROBENECID; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEICOPLANIN; TEMAFLOXACIN; THEOPHYLLINE; TROVAFLOXACIN; ULIFLOXACIN; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOTOXICITY; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CHRONIC PROSTATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYSTITIS; DIABETIC FOOT; DIARRHEA; DISEASE EXACERBATION; DISK DIFFUSION; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GYNECOLOGIC INFECTION; HUMAN; LIVER TOXICITY; MILK; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SKIN DISEASE; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; ADULT; AGED; DRUG EFFECT; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; MALE; MICROBIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADULT; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DIOXOLANES; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 61749102100     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.4.1.13     Document Type: Article

References (58)

1. Andriole VT: The quinolones: past, present, and future. Clin. Infect. Dis. 41(Suppl. 2), S113-S119 (2005).
2. Mandell LA, Wunderink RG, Anzueto A et al.: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
3. Chroneou A, Zias N, Beamis JF Jr, Craven DE: Healthcare-associated pneumonia: principles and emerging concepts on management. Expert Opin Pharmacother. 8, 3117-3131 (2007).
4. Zavascki AP, Goldani LZ, Li J, Nation RL: Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60, 1206-1215 (2007).
5. Tascini C, Menichetti F, Gemignani G et al.: Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis. Int. J. Low Extrem. Wounds 5, 213-216 (2006).
6. Keam SJ, Perry CM: Prulifloxacin. Drugs 64, 2221-2234 (2004).
7. Matera MG: Pharmacologic characteristics of prulifloxacin. Pulm. Pharmacol. Ther. 19(Suppl. 1), 20-29 (2006).
8. Prats G, Rossi V, Salvatori E, Mirelis B: Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev. Anti. Infect. Ther. 4, 27-41 (2006).
9. Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L: Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int. J. Chron. Obstruct. Pulmon. Dis. 2, 27-31 (2007).
10. Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A: Paraoxonase has a major role in-the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab. Dispos. 26, 355-359 (1998).
11. Yoshida T, Mitsuhashi S: Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob. Agents Chemother. 37, 793-800 (1993).
12. Hooper DC: Mode of action of fluoroquinolones. Drugs 58(Suppl. 2), 6-10 (1999).
13. Okuyama Y, Momota K, Morino A: Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Anzneimittelforschung 47, 276-284 (1997).
14. Okuyama Y, Momota K, Morino A: Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats. Arzneimittelforschung 47, 285-292 (1997).
15. Okuyama Y, Morino A: Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys. Arzneimittelforschung 47, 293-298 (1997).
16. Nakashima M, Uematsu T, Kosuge K et al.: Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J. Clin. Pharmacol. 34, 930-937 (1994).
17. Saito A, Tarao F: Influence of milk on absorption of NM 441, a prodrug type of quinolone antibiotic. Jpn. J. Chemother. 44(Suppl. 1), 221-228 (1996).
18. Shiba K, Yoshida M, Sakai O, Saito A: Pharmacokinetics and clinical studies on NM441. Jpn. J. Chemother. 44(Suppl. 1), 263-278 (1996).
19. Totsuka K, Kikuchi K, Shimizu K: Pharmacokinetics in concomitant administration with probenecid and clinical study of NM441. Jpn. J. Chemother. 44 (Suppl. 1), 279-288 (1996).
20. Fattore C, Cipolla G, Gatti G et al.: Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers. Clin. Drug Investig. 16, 387-392 (1998).
21. Picollo R, Brion N, Gualano V et al.: Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 53, 201-205 (2003).
22. Gorlero F, Lorenzi P, Rosignon MT et al.: Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. Drugs R. D. 8, 373-381 (2007).
23. Tanimura H, Ishimoto K, Murakami K, Uchiyama K, Iwakura S: Penetration of NM441, a new quinolone, into human bile and gallbladder tissue. Drugs 49(Suppl. 2), 337-340 (1995).
24. Concia E, Allegranzi B, Ciottoli GB, Orticelli G, Marchetti M, Dionisio P: Penetration of orally administered prulifloxacin into human lung tissue. Clin. Pharmacokinet. 44, 1287-1294 (2005).
25. Ozaki M, Komori K, Matsuda M et al.: Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 40, 739-742 (1996).
26. Tullio V, Cuffini AM, Bonino A, Ianni Palarchio A, Rossi V, Carlone NA: Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae. Drugs Exp. Clin. Res. 25, 1-11 (1999).
27. Shimizu M, Tabata M, Hara T, Araake M, Watabe H, Nishino T: In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin. Jpn. J. Antibiotic. 55, 791-799 (2002).
28. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. 5th ed. National Committee for Clinical Laboratory Standards, Wayne, PA, USA (2000).
29. National Committee for Clinical Laboratory Standards: MIC testing supplemental tables. M100-S10 (M7). National Committee for Clinical Laboratory Standards, Wayne, PA, USA (2000).
30. Ozaki M, Matsuda M, Tomii Y et al.: In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob. Agents Chemother. 35, 2496-2499 (1991) (Erratum in: Antimicrob. Agents Chemother. 36, 1170 [1992] and Antimicrob. Agents Chemother. 37, 930 [1993]).
31. Montanari MP, Mingoia M, Varaldo PE: In vitro antibacterial activities of AF3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob. Agents Chemother. 45, 3616-3622 (2001).
32. Prats G, Roig C, Miro E, Navarro F, Mirelis B: In vitro activity of the active/metabolite of prulifloxacin (AE3013) compared with six other fluoroquinolones. Eur. J. Clin. Microbiol. Infect. Dis. 21, 328-334 (2002) (Erratum in: Eur. J. Clin. Microbiol. Infect. Dis. 23, 422 [2004]).
33. Montanari MP, Ferrante L, Tili E, Cochetti I, Rossi V, Varaldo PE: Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxarin. J. Chemother. 17, 138-142 (2005).
34. Roveta S, Schito AM, Marchese A, Schito GC: Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 26, 366-372 (2005).
35. Ceccarini P, Capezzone de Joannon A, Rossi V: Antibiotic susceptibility of Pseudomonas aeruginosa biofilm to ulifloxacin and other fluoroquinolones. Clin. Microbiol. Infect. 14(Suppl. 7), S671 (2008).
36. Gemignani G, Tascini C, Leonildi A, Piaggesi A, Menichetti F: Activity of ulifloxacin against clinical hospital isolates. Infez. Med. 15, 169-173 (2007).
37. Fritsche TR, Biedenbach DJ, Jones RN: In vitro activity of ulifloxacin (active metabolite of prulifloxacin) tested against a worldwide collection of pathogen producing traveler's diarrhea. Proceedings of: The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
38. Blondeau JM, Zhao X, Hansen G, Drlica K: Mutant prevention concentrations of fluoroquinoiones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433-438 (2001).
39. Gualco L, Schito AM, Schito GC, Marchese A: In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance, Int. J. Antimicrob. Agents 29, 679-687 (2007).
40. Nishino T, Tomii Y, Shibata K et al.: In vitro and in vivo antibacterial activity of NM441. Jpn, J. Chemother. 44 (Suppl. 1), 56-69 (1996).
41. Tomii Y, Ozaki M, Matsuda M et al.: Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Arzneimittelforschung 46, 1169-1173 (1996).
42. Grassi C, Salvatori E, Rosignoli MT, Dionisio P: Prulifloxacin Study Group: randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 69, 217-222 (2002).
43. Cervigni M, Orticelli G, Bologna M et al.: Single-dose prulifloxacin versus single-dose pefloxacin in the treatment of acute uncomplicated urinary tract infection in women. Urogynaecol. Int. J. 17, 69-77 (2003).
44. Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P: Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol. Int. 74, 326-331 (2005).
45. Giannarini G, Mogorovich A, Valent F et al.: Prulifloxacin versus, levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J. Chemother. 19, 304-308 (2007).
46. Reato G, Cuffini AM, Tullio V et al.: Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. Int. J. Antimicrob. Agents 23, 150-154 (2004).
47. Cavani E, Paura C: The diabetic infected foot. Outpatients management and experience with prulifloxacin. Trends Med. 7, 139-147 (2007).
48. Owens RC Jr, Ambrose PG: Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 41(Suppl. 2), S144-S157 (2005).
49. Bertino J Jr, Fish D: The safety profile of the fluoroquinolones. Clin. Ther. 22, 798-817 (2000).
50. Mehlhorn AJ, Brown DA: Safety concerns with fluoroquinolones. Ann. Pharmacother. 41, 1859-1866 (2007).
51. Prins JM, Koopmans RP: Novel side effects of moxifloxacin: making a balanced decision again. Ned. Tijdschr. Geneeskd. 152, 1862-1864 (2008).
52. Lacroix P, Crumb WJ, Durando L, Ciottoli GB: Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur. J. Pharmacol. 477, 69-72 (2003).
53. Akita M, Shibazaki Y, Izumi M et al.: Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J. Toxicol. Sci. 29, 63-71 (2004):
54. Ukai Y, Yamazaki A, Kurosaka C, Ishima T, Yoshikuni Y, Kimura K: Convulsant effects of NM441, aprodrug type antibacterial agent of the quinolone class. Jpn. J. Chemother. 44(Suppl. 1), 102-112 (1996).
55. Kura K, Fukui T, Okamoto M et al.: General pharmacological studies of NM441. (1) Effects on central and peripheral nervous systems, gastrointestinal tract and smooth muscle. Jpn. J. Chemother. 44(Suppl. 1), 113-128 (1996).
56. Kura K, Ochi S, Tanaka M et al.: General pharmacological studies of NM441. (2) Effects on respiratory and cardiovascular systems, renal function and others. Jpn. J, Chemother. 44(Suppl. 1), 129-146 (1996).
57. Gallelli L, Gallelli A, Vero G et al.: Acute renal failure probably induced by prulinoxacin in an elderly woman: a first case report. Clin. Drug Investig. 26, 49-53 (2006).
58. Prulifloxacin approved in Japan. Scrip 2790, 22 (2002).